MSD obtains Singapore HSA interim authorisation for Covid-19 antiviral

MSD (Merck in North America) has obtained interim authorisation under the Pandemic Special Access Route (PSAR) from Singapore Health Sciences Authority (HSA) for its antiviral medicine Lagevrio (molnupiravir) to treat Covid-19. Lagevrio is the second oral antiviral therapy to obtain authorisation in the region to treat mild to moderate Covid-19 in people of the age 18 years and above. It is intended for patients who are at risk of disease progression to severe Covid-19 and/or hospital admission and for those with no clinically appropriate substitute Covid-19 treatment options available.